Quinidine exhibits differential blocking potency between hEAG1 and hEAG2, providing a pharmacological tool to distinguish these potassium channel isoforms.
No takes yet. Share an insight, caveat, or question.
Quinidine offers a tool to distinguish hEAG isoforms in vitro; leaves open any cardiac or therapeutic relevance in humans.
Schönherr et al. (2002) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: